1. Home
  2. SGHT vs SVII Comparison

SGHT vs SVII Comparison

Compare SGHT & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGHT
  • SVII
  • Stock Information
  • Founded
  • SGHT 2011
  • SVII 2021
  • Country
  • SGHT United States
  • SVII United States
  • Employees
  • SGHT N/A
  • SVII N/A
  • Industry
  • SGHT Medical Specialities
  • SVII Blank Checks
  • Sector
  • SGHT Health Care
  • SVII Finance
  • Exchange
  • SGHT Nasdaq
  • SVII Nasdaq
  • Market Cap
  • SGHT 304.4M
  • SVII 252.5M
  • IPO Year
  • SGHT 2021
  • SVII 2022
  • Fundamental
  • Price
  • SGHT $3.76
  • SVII $11.23
  • Analyst Decision
  • SGHT Buy
  • SVII
  • Analyst Count
  • SGHT 6
  • SVII 0
  • Target Price
  • SGHT $6.80
  • SVII N/A
  • AVG Volume (30 Days)
  • SGHT 264.4K
  • SVII 134.4K
  • Earning Date
  • SGHT 11-07-2024
  • SVII 01-01-0001
  • Dividend Yield
  • SGHT N/A
  • SVII N/A
  • EPS Growth
  • SGHT N/A
  • SVII N/A
  • EPS
  • SGHT N/A
  • SVII N/A
  • Revenue
  • SGHT $79,543,000.00
  • SVII N/A
  • Revenue This Year
  • SGHT $3.06
  • SVII N/A
  • Revenue Next Year
  • SGHT $10.33
  • SVII N/A
  • P/E Ratio
  • SGHT N/A
  • SVII $12.50
  • Revenue Growth
  • SGHT N/A
  • SVII N/A
  • 52 Week Low
  • SGHT $2.58
  • SVII $10.78
  • 52 Week High
  • SGHT $8.45
  • SVII $11.70
  • Technical
  • Relative Strength Index (RSI)
  • SGHT 31.07
  • SVII 34.95
  • Support Level
  • SGHT $3.65
  • SVII $11.20
  • Resistance Level
  • SGHT $3.85
  • SVII $11.37
  • Average True Range (ATR)
  • SGHT 0.29
  • SVII 0.05
  • MACD
  • SGHT -0.04
  • SVII -0.04
  • Stochastic Oscillator
  • SGHT 7.14
  • SVII 6.00

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

About SVII Spring Valley Acquisition Corp. II

Spring Valley Acquisition Corp II is a blank check company.

Share on Social Networks: